4lge
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | + | ==Crystal structure of clAP1 BIR3 bound to T3261256== | |
- | + | <StructureSection load='4lge' size='340' side='right' caption='[[4lge]], [[Resolution|resolution]] 1.55Å' scene=''> | |
- | { | + | == Structural highlights == |
+ | <table><tr><td colspan='2'>[[4lge]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LGE OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4LGE FirstGlance]. <br> | ||
+ | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1Y0:(4S,6AR,7AS)-5-{(2S)-2-CYCLOHEXYL-2-[(N-METHYL-L-ALANYL)AMINO]ACETYL}-N-[(4R)-3,4-DIHYDRO-2H-CHROMEN-4-YL]OCTAHYDRO-1H-CYCLOPROPA[4,5]PYRROLO[1,2-A]PYRAZINE-4-CARBOXAMIDE'>1Y0</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | ||
+ | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4lgu|4lgu]]</td></tr> | ||
+ | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">API1, BIRC2, IAP2, MIHB, RNF48 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])</td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4lge FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4lge OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4lge RCSB], [http://www.ebi.ac.uk/pdbsum/4lge PDBsum]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | We recently reported the discovery of octahydropyrrolo[1,2-a]pyrazine A as a lead compound for an inhibitor of apoptosis proteins (IAP) antagonist. To develop IAP antagonists with favorable PK profiles, we designed novel tri-cyclic compounds, octahydro-1H-cyclopropa[4,5]pyrrolo[1,2-a]pyrazines 1 and 2 based on co-crystal structural analysis of A with cellular IAP-1 (cIAP-1). The additional cyclopropane moiety was used to block the predicted metabolic site of compound A without detriment to the binding affinity for cIAP. Compounds 1 and 2 were stereoselectively synthesized via intermediates 4a and 5b', which were obtained by Simmons-Smith cyclopropanation of ethylester 3a and silyl ether 3b'. Compounds 1 and 2 showed strong growth inhibition in MDA-MB-231 breast cancer cells and improved metabolic stability in comparison to A. Compound 2 exhibited significant in vivo PD effects to increase tumor necrosis factor-alpha mRNA in a dose dependent manner. | ||
- | + | Design, stereoselective synthesis, and biological evaluation of novel tri-cyclic compounds as inhibitor of apoptosis proteins (IAP) antagonists.,Asano M, Hashimoto K, Saito B, Shiokawa Z, Sumi H, Yabuki M, Yoshimatsu M, Aoyama K, Hamada T, Morishita N, Dougan DR, Mol CD, Yoshida S, Ishikawa T Bioorg Med Chem. 2013 Sep 15;21(18):5725-37. doi: 10.1016/j.bmc.2013.07.020. Epub, 2013 Jul 18. PMID:23928071<ref>PMID:23928071</ref> | |
- | + | ||
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | </div> | |
- | + | == References == | |
- | == | + | <references/> |
- | + | __TOC__ | |
+ | </StructureSection> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
- | [[Category: Dougan, D R | + | [[Category: Dougan, D R]] |
- | [[Category: | + | [[Category: Card domain]] |
- | [[Category: | + | [[Category: Ring-type zinc finger]] |
- | [[Category: | + | [[Category: Bir repeat]] |
[[Category: Lap family]] | [[Category: Lap family]] | ||
[[Category: Ligase-ligase inhibitor complex]] | [[Category: Ligase-ligase inhibitor complex]] |
Revision as of 15:15, 21 December 2014
Crystal structure of clAP1 BIR3 bound to T3261256
|